Breaking Finance News

A statement released earlier today by Zacks Investment Research about Global Blood Therapeutics Inc (NASDAQ:GBT) bumps the target price to $20.00

Zacks Investment Research bumped up the target of Global Blood Therapeutics Inc (NASDAQ:GBT) to $20.00 stating a potential upside of 0.10%.

Boasting a price of $18.25, Global Blood Therapeutics Inc (NASDAQ:GBT) traded -3.85% lower on the day. With the last stock price close down -10.21% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Global Blood Therapeutics Inc has recorded a 50-day average of $19.98 and a two hundred day average of $19.49. Volume of trade was down over the average, with 397,639 shares of GBT changing hands under the typical 431,388

Performance Chart

Global Blood Therapeutics Inc (NASDAQ:GBT)

With a total market value of $0, Global Blood Therapeutics Inc has with a one year low of $12.24 and a one year high of $55.74 .

A total of 4 equity analysts have released a ratings update on GBT. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $59.75.

Brief Synopsis About Global Blood Therapeutics Inc (NASDAQ:GBT)

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company's segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.